The role of osteopontin in breast cancer: Clinical and experimental studies

被引:128
作者
Tuck, AB
Chambers, AF
机构
[1] London Reg Canc Ctr, London, ON N6A 4L6, Canada
[2] Univ Western Ontario, Dept Oncol, London, ON, Canada
[3] Univ Western Ontario, Dept Pathol, London, ON, Canada
[4] London Hlth Sci Ctr, Dept Pathol, London, ON, Canada
关键词
breast cancer; malignancy; osteopontin; experimental studies; clinical studies; prognostic factor;
D O I
10.1023/A:1014734930781
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Osteopontin (OPN) is a secreted, integrin-binding protein which has been implicated in cancer, as well as other pathologies and some aspects of normal development. Here we focus on the role of OPN in breast cancer. We describe studies that have shown that OPN plays a role in normal mammary gland development as well as in progression of breast cancer. We also summarize studies that have shown that OPN can play a functional role in malignancy of breast cancer. At least some of these effects are mediated by specific cell surface integrins (alphavbeta3 vs. alphavbeta1 and alphavbeta5) and lead to increased cell migration, activation of growth factor/receptor pathways (e.g. HGF and EGF), and increased proteolytic enzyme activity (e.g. uPA). We also summarize clinical studies that show that OPN levels in tumors and blood are elevated in women with metastatic breast cancer and may offer promise as prognostic markers in breast cancer.
引用
收藏
页码:419 / 429
页数:11
相关论文
共 96 条
[1]   Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin) [J].
Agnihotri, R ;
Crawford, HC ;
Haro, H ;
Matrisian, LM ;
Havrda, MC ;
Liaw, L .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (30) :28261-28267
[2]  
Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO
[3]  
2-Z
[4]   Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity [J].
Ashkar, S ;
Weber, GF ;
Panoutsakopoulou, V ;
Sanchirico, ME ;
Jansson, M ;
Zawaideh, S ;
Rittling, SR ;
Denhardt, DT ;
Glimcher, MJ ;
Cantor, H .
SCIENCE, 2000, 287 (5454) :860-864
[5]  
Baik MG, 1998, INT J MOL MED, V2, P39
[6]  
BAND V, 1990, CANCER RES, V50, P7351
[7]   Gains and losses of CD44 expression during breast carcinogenesis and tumour progression [J].
Bankfalvi, A ;
Terpe, HJ ;
Breukelmann, D ;
Bier, B ;
Rempe, D ;
Pschadka, G ;
Krech, R ;
Böcker, W .
HISTOPATHOLOGY, 1998, 33 (02) :107-116
[8]   A regulated interaction between α5β1 integrin and osteopontin [J].
Barry, ST ;
Ludbrook, SB ;
Murrison, E ;
Horgan, CMT .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 267 (03) :764-769
[9]   Quantification of osteopontin in human plasma with an ELISA: Basal levels in pre- and postmenopausal women [J].
Bautista, DS ;
Saad, Z ;
Chambers, AF ;
Tonkin, KS ;
OMalley, FP ;
Singhal, H ;
Tokmakejian, S ;
Bramwell, V ;
Harris, JF .
CLINICAL BIOCHEMISTRY, 1996, 29 (03) :231-239
[10]  
BAUTISTA DS, 1994, J BIOL CHEM, V269, P23280